Reference Bibilography

DED References

  1. Curtis TM, Gardiner TA, Stitt AW. Microvascular lesions of diabetic retinopathy: Clues towards understanding pathogenesis? Eye (Lond). 2009;23(7):1496-1508. doi: 10.1038/eye.2009.108 [doi].
  2. Okamoto F, Sone H, Nonoyama T, Hommura S. Refractive changes in diabetic patients during intensive glycaemic control. Br J Ophthalmol. 2000;84(10):1097-1102.
  3. Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3):556-564. doi: 10.2337/dc11-1909 [doi].
  4. Do DV, Wang X, Vedula SS, et al. Blood pressure control for diabetic retinopathy. Cochrane Database Syst Rev. 2015;1:CD006127. doi: 10.1002/14651858.CD006127.pub2 [doi].
  5. Sivaprasad S, Gupta B, Crosby-Nwaobi R, Evans J. Prevalence of diabetic retinopathy in various ethnic groups: A worldwide perspective. Surv Ophthalmol. 2012;57(4):347-370. doi: 10.1016/j.survophthal.2012.01.004 [doi].
  6. ERROR
  7. Song BJ, Aiello LP, Pasquale LR. Presence and risk factors for glaucoma in patients with diabetes. Curr Diab Rep. 2016;16(12):124-016-0815-6. doi: 10.1007/s11892-016-0815-6 [doi].
  8. Zhao YX, Chen XW. Diabetes and risk of glaucoma: Systematic review and a meta-analysis of prospective cohort studies. Int J Ophthalmol. 2017;10(9):1430-1435. doi: 10.18240/ijo.2017.09.16 [doi].
  9. Halilovic EA, Ljaljevic S, Alimanovic I, Mavija M, Oros A, Nisic F. Analysis of the influence of type of diabetes mellitus on the development and type of glaucoma. Med Arch. 2015;69(1):34-37. doi: 10.5455/medarh.2015.69.34-37 [doi].
  10. Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: A systematic review and meta-analysis. Ophthalmology. 2014;121(11):2081-2090. doi: 10.1016/j.ophtha.2014.05.013 [doi].
  11. Pollreisz A, Schmidt-Erfurth U. Diabetic cataract-pathogenesis, epidemiology and treatment. J Ophthalmol. 2010;2010:608751. doi: 10.1155/2010/608751 [doi].
  12. Saxena S, Mitchell P, Rochtchina E. Five-year incidence of cataract in older persons with diabetes and pre-diabetes. Ophthalmic Epidemiol. 2004;11(4):271-277. doi: H8U4MAMNCDK0G24U [pii].
  13. Javadi MA, Zarei-Ghanavati S. Cataracts in diabetic patients: A review article. J Ophthalmic Vis Res. 2008;3(1):52-65.
  14. Klein BE, Klein R, Moss SE. Incidence of cataract surgery in the wisconsin epidemiologic study of diabetic retinopathy. Am J Ophthalmol. 1995;119(3):295-300. doi: S0002-9394(14)71170-5 [pii].
  15. Klein BE, Klein R, Wang Q, Moss SE. Older-onset diabetes and lens opacities. the beaver dam eye study. Ophthalmic Epidemiol. 1995;2(1):49-55.
  16. Liu Y, Luo L, He M, Liu X. Disorders of the blood-aqueous barrier after phacoemulsification in diabetic patients. Eye (Lond). 2004;18(9):900-904. doi: 10.1038/sj.eye.6701349 [doi].
  17. Schafer C, Lautenschlager C, Struck HG. Cataract types in diabetics and non-diabetics: A densitometric study with the topcon-scheimpflug camera. Klin Monbl Augenheilkd. 2006;223(7):589-592. doi: 10.1055/s-2006-926515 [doi].
  18. Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis (Lond). 2015;2:17-015-0026-2. eCollection 2015. doi: 10.1186/s40662-015-0026-2 [doi].
  19. Becker C, Schneider C, Aballea S, et al. Cataract in patients with diabetes mellitus-incidence rates in the UK and risk factors. Eye (Lond). 2018;32(6):1028-1035. doi: 10.1038/s41433-017-0003-1 [doi].
  20. Dedov I, Maslova O, Suntsov Y, Bolotskaia L, Milenkaia T, Besmertnaia L. Prevalence of diabetic retinopathy and cataract in adult patients with type 1 and type 2 diabetes in russia. Rev Diabet Stud. 2009;6(2):124-129. doi: 10.1900/RDS.2009.6.124 [doi].
  21. Lemp MA. Advances in understanding and managing dry eye disease. Am J Ophthalmol. 2008;146(3):350-356. doi: 10.1016/j.ajo.2008.05.016 [doi].
  22. Gekka M, Miyata K, Nagai Y, et al. Corneal epithelial barrier function in diabetic patients. Cornea. 2004;23(1):35-37.
  23. Zhang X, Zhao L, Deng S, Sun X, Wang N. Dry eye syndrome in patients with diabetes mellitus: Prevalence, etiology, and clinical characteristics. J Ophthalmol. 2016;2016:8201053. doi: 10.1155/2016/8201053 [doi].
  24. Fuerst N, Langelier N, Massaro-Giordano M, et al. Tear osmolarity and dry eye symptoms in diabetics. Clin Ophthalmol. 2014;8:507-515. doi: 10.2147/OPTH.S51514 [doi].
  25. McLaughlin PJ, Sassani JW, Klocek MS, Zagon IS. Diabetic keratopathy and treatment by modulation of the opioid growth factor (OGF)-OGF receptor (OGFr) axis with naltrexone: A review. Brain Res Bull. 2010;81(2-3):236-247. doi: 10.1016/j.brainresbull.2009.08.008 [doi].
  26. Krishna, U., et al., Uveitis: a sight-threatening disease which can impact all systems.Postgrad Med J, 2017. 93(1106): p. 766-773.
  27. Durrani, O.M., et al., Degree, duration, and causes of visual loss in uveitis.Br J Ophthalmol, 2004. 88(9): p. 1159-62.
  28. National Eye Institute (https://nei.nih.gov/health/uveitis/uveitis).
  29. Gutteridge, I.F. and A.J. Hall, Acute anterior uveitis in primary care.Clin Exp Optom, 2007. 90(2): p. 70-82.
  30. Tsirouki, T., et al., A Focus on the Epidemiology of Uveitis.Ocul Immunol Inflamm, 2018. 26(1): p. 2-16.
  31. Rottgers, E. and N.R. Holdeman, An unusual case of chorioretinitis in a diabetic patient.Clin Exp Optom, 2009. 92(2): p. 142-5.
  32. Sinha, M.K., R. Narayanan, and J.K. Chhablani, Hypopyon uveitis following panretinal photocoagulation in a diabetic patient.Semin Ophthalmol, 2014. 29(3): p. 166-8.
  33. Takahashi, Y., et al., Severe anterior uveitis associated with idiopathic dacryoadenitis in diabetes mellitus patient.Clin Ophthalmol, 2011. 5: p. 619-21.
  34. Tyagi, M., V. Ambiya, and P.K. Rani, Hypopyon uveitis following panretinal photocoagulation.BMJ Case Rep, 2016. 2016.
  35. Rothova, A., et al., Uveitis and diabetes mellitus.Am J Ophthalmol, 1988. 106(1): p. 17-20.
  36. Herranz, M.T., et al., Increased prevalence of NIDDM in anterior uveitis.Diabetes Care, 1997. 20(11): p. 1797-8.
  37. Kheir, W.J., H.A. Sheheitli, and R.N. Hamam, Intraocular Inflammation in Diabetic Populations.Curr Diab Rep, 2017. 17(10): p. 83.
  38. Oswal, K.S., et al., Clinical course and visual outcome in patients with diabetes mellitus and uveitis.BMC Res Notes, 2013. 6: p. 167.
  39. BMJ Best Practice. Uveitis (https://bestpractice.bmj.com/). Accessed 11 December 2018
  40. Yau, J.W., et al., Global prevalence and major risk factors of diabetic retinopathy.Diabetes Care, 2012. 35(3): p. 556-64.
  41. Lee, R., T.Y. Wong, and C. Sabanayagam, Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss.Eye Vis (Lond), 2015. 2: p. 17.
  42. Leasher, J.L., et al., Global Estimates on the Number of People Blind or Visually Impaired by Diabetic Retinopathy: A Meta-analysis From 1990 to 2010.Diabetes Care, 2016. 39(9): p. 1643-9.
  43. Fong, D.S., et al., Diabetic retinopathy.Diabetes Care, 2003. 26 Suppl 1: p. S99-S102.
  44. Thomas, R.L., et al., Retrospective analysis of newly recorded certifications of visual impairment due to diabetic retinopathy in Wales during 2007-2015.BMJ Open, 2017. 7(7): p. e015024.
  45. Fathy, C., et al., Disparities in Adherence to Screening Guidelines for Diabetic Retinopathy in the United States: A Comprehensive Review and Guide for Future Directions.Semin Ophthalmol, 2016. 31(4): p. 364-77.
  46. Malerbi, F.K., et al., Comparison between binocular indirect ophthalmoscopy and digital retinography for diabetic retinopathy screening: the multicenter Brazilian Type 1 Diabetes Study.Diabetol Metab Syndr, 2015. 7: p. 116.
  47. Wang, L.Z., et al., Availability and variability in guidelines on diabetic retinopathy screening in Asian countries.Br J Ophthalmol, 2017. 101(10): p. 1352-1360.
  48. Wong, I.Y.H., et al., Saving sight in China and beyond: the Lifeline Express model.BMJ Glob Health, 2018. 3(4): p. e000766.
  49. Tanaka, H., et al., Process quality of diabetes care under favorable access to healthcare: a 2-year longitudinal study using claims data in Japan.BMJ Open Diabetes Res Care, 2016. 4(1): p. e000291.
  50. Mash, B., et al., Screening for diabetic retinopathy in primary care with a mobile fundal camera–evaluation of a South African pilot project.S Afr Med J, 2007. 97(12): p. 1284-8.
  51. Cleland, C.R., et al., Diabetic retinopathy screening: experiences from northern Tanzania.Lancet Diabetes Endocrinol, 2016. 4(1): p. 10-2.
  52. Fong DS, Aiello LP, Ferris FL,3rd, Klein R. Diabetic retinopathy. Diabetes Care. 2004;27(10):2540-2553. doi: 27/10/2540 [pii].
  53. Fenwick E, Rees G, Pesudovs K, et al. Social and emotional impact of diabetic retinopathy: A review. Clin Exp Ophthalmol. 2012;40(1):27-38. doi: 10.1111/j.1442-9071.2011.02599.x [doi].
  54. Chen E, Looman M, Laouri M, et al. Burden of illness of diabetic macular edema: Literature review. Curr Med Res Opin. 2010;26(7):1587-1597. doi: 10.1185/03007995.2010.482503 [doi].
  55. Kaminsky TA, Mitchell PH, Thompson EA, Dudgeon BJ, Powell JM. Supports and barriers as experienced by individuals with vision loss from diabetes. Disabil Rehabil. 2014;36(6):487-496. doi: 10.3109/09638288.2013.800592 [doi].
  56. Schmier JK, Covert DW, Matthews GP, Zakov ZN. Impact of visual impairment on service and device use by individuals with diabetic retinopathy. Disabil Rehabil. 2009;31(8):659-665. doi: 10.1080/09638280802239391 [doi].
  57. Heintz E, Wirehn AB, Peebo BB, Rosenqvist U, Levin LA. Prevalence and healthcare costs of diabetic retinopathy: A population-based register study in sweden. Diabetologia. 2010;53(10):2147-2154. doi: 10.1007/s00125-010-1836-3 [doi].
  58. Woung LC, Tsai CY, Chou HK, et al. Healthcare costs associated with progressive diabetic retinopathy among national health insurance enrollees in taiwan, 2000-2004. BMC Health Serv Res. 2010;10:136-6963-10-136. doi: 10.1186/1472-6963-10-136 [doi].
  59. Devenney R, O’Neill S. The experience of diabetic retinopathy: A qualitative study. Br J Health Psychol. 2011;16(4):707-721. doi: 10.1111/j.2044-8287.2010.02008.x [doi].
  60. Schmitt-Koopmann I, Schwenkglenks M, Spinas GA, Szucs TD. Direct medical costs of type 2 diabetes and its complications in switzerland. Eur J Public Health. 2004;14(1):3-9.
  61. Happich M, Reitberger U, Breitscheidel L, Ulbig M, Watkins J. The economic burden of diabetic retinopathy in germany in 2002. Graefes Arch Clin Exp Ophthalmol. 2008;246(1):151-159. doi: 10.1007/s00417-007-0573-x [doi].
  62. Schmier JK, Covert DW, Lau EC, Matthews GP. Medicare expenditures associated with diabetes and diabetic retinopathy. Retina. 2009;29(2):199-206. doi: 10.1097/IAE.0b013e3181884f2d [doi].
  63. Javitt, J.C. and L.P. Aiello, Cost-effectiveness of detecting and treating diabetic retinopathy.Ann Intern Med, 1996. 124(1 Pt 2): p. 164-9.
  64. Sculpher, M.J., et al., Screening for diabetic retinopathy: a relative cost-effectiveness analysis of alternative modalities and strategies.Health Econ, 1992. 1(1): p. 39-51.
  65. Jones, S. and R.T. Edwards, Diabetic retinopathy screening: a systematic review of the economic evidence.Diabet Med, 2010. 27(3): p. 249-56.
  66. Ting, D.S., G.C. Cheung, and T.Y. Wong, Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review.Clin Exp Ophthalmol, 2016. 44(4): p. 260-77.
  67. Wong, T.Y., et al., Guidelines on Diabetic Eye Care: The International Council of Ophthalmology Recommendations for Screening, Follow-up, Referral, and Treatment Based on Resource Settings.Ophthalmology, 2018. 125(10): p. 1608-1622.
  68. Burgess, P.I., G. Msukwa, and N.A. Beare, Diabetic retinopathy in sub-Saharan Africa: meeting the challenges of an emerging epidemic.BMC Med, 2013. 11: p. 157.
  69. Strutton, R., et al., System-level and patient-level explanations for non-attendance at diabetic retinopathy screening in Sutton and Merton (London, UK): a qualitative analysis of a service evaluation.BMJ Open, 2016. 6(5): p. e010952.
  70. Kashim, R.M., P. Newton, and O. Ojo, Diabetic Retinopathy Screening: A Systematic Review on Patients’ Non-Attendance.Int J Environ Res Public Health, 2018. 15(1).
  71. Dickinson J. The Experience of Diabetes-Related Language in Diabetes Care. Diabetes Spectrum. 2017;31(1):58-64. doi:10.2337/ds16-0082
  72. Dickinson J, Guzman S, Maryniuk M et al. The Use of Language in Diabetes Care and Education. Diabetes Care. 2017;40(12):1790-1799. doi:10.2337/dci17-0041
  73. Cheung, N., Mitchell, P. and Wong, T. Y. (2010) ‘Diabetic retinopathy’, in The Lancet. doi: 10.1016/S0140-6736(09)62124-3.
  74. Tozer, K., M.A. Woodward, and P.A. Newman-Casey, Telemedicine and Diabetic Retinopathy: Review of Published Screening Programs.J Endocrinol Diabetes, 2015. 2(4).
  75. Jani, P.D., et al., Evaluation of Diabetic Retinal Screening and Factors for Ophthalmology Referral in a Telemedicine Network.JAMA Ophthalmol, 2017. 135(7): p. 706-714.
  76. Pasquel, F.J., et al., Cost-effectiveness of Different Diabetic Retinopathy Screening Modalities.J Diabetes Sci Technol, 2015. 10(2): p. 301-7.
  77. Pasquel, F.J., et al., Cost-effectiveness of Different Diabetic Retinopathy Screening Modalities.J Diabetes Sci Technol, 2015. 10(2): p. 301-7.
  78. Li, Z., et al., Telemedicine-based digital retinal imaging vs standard ophthalmologic evaluation for the assessment of diabetic retinopathy.Conn Med, 2012. 76(2): p. 85-90.
  79. Khan, T., et al., Preventing diabetes blindness: cost effectiveness of a screening programme using digital non-mydriatic fundus photography for diabetic retinopathy in a primary health care setting in South Africa.Diabetes Res Clin Pract, 2013. 101(2): p. 170-6.
  80. Micheletti, J.M., et al., Current and Next Generation Portable Screening Devices for Diabetic Retinopathy.J Diabetes Sci Technol, 2016. 10(2): p. 295-300.
  81. Ryan, M.E., et al., Comparison Among Methods of Retinopathy Assessment (CAMRA) Study: Smartphone, Nonmydriatic, and Mydriatic Photography.Ophthalmology, 2015. 122(10): p. 2038-43.
  82. Scotland, G.S., et al., Cost-effectiveness of implementing automated grading within the national screening programme for diabetic retinopathy in Scotland.Br J Ophthalmol, 2007. 91(11): p. 1518-23.
  83. Keel, S., et al., Feasibility and patient acceptability of a novel artificial intelligence-based screening model for diabetic retinopathy at endocrinology outpatient services: a pilot study.Sci Rep, 2018. 8(1): p. 4330.
  84. van der Heijden, A.A., et al., Validation of automated screening for referable diabetic retinopathy with the IDx-DR device in the Hoorn Diabetes Care System.Acta Ophthalmol, 2018. 96(1): p. 63-68.
  85. Goh, J.K., et al., Retinal Imaging Techniques for Diabetic Retinopathy Screening.J Diabetes Sci Technol, 2016. 10(2): p. 282-94.
  86. Ishibazawa, A., et al., Optical Coherence Tomography Angiography in Diabetic Retinopathy: A Prospective Pilot Study.Am J Ophthalmol, 2015. 160(1): p. 35-44 e1.
  87. Ghasemi Falavarjani, K., et al., Ultra-wide-field imaging in diabetic retinopathy; an overview.J Curr Ophthalmol, 2016. 28(2): p. 57-60.
  88. Wessel, M.M., et al., Ultra-wide-field angiography improves the detection and classification of diabetic retinopathy.Retina, 2012. 32(4): p. 785-91.
  89. Blair, N.P., et al., Retinal Oximetry and Vessel Diameter Measurements With a Commercially Available Scanning Laser Ophthalmoscope in Diabetic Retinopathy.Invest Ophthalmol Vis Sci, 2017. 58(12): p. 5556-5563.
  90. Fenner, B.J., et al., Advances in Retinal Imaging and Applications in Diabetic Retinopathy Screening: A Review.Ophthalmol Ther, 2018. 7(2): p. 333-346.
  91. Simo, R., et al., Effects of Topically Administered Neuroprotective Drugs in Early Stages of Diabetic Retinopathy. Results of the EUROCONDOR Clinical Trial.Diabetes, 2018.
  92. Final Report Summary – EUROCONDOR (European Consortium for the Early Treatment of Diabetic Retinopathy). https://cordis.europa.eu/result/rcn/189871_en.html.
  93. Patel, J.I., et al., Angiopoietin concentrations in diabetic retinopathy.Br J Ophthalmol, 2005. 89(4): p. 480-3.
  94. Campochiaro, P.A., et al., Enhanced Benefit in Diabetic Macular Edema from AKB-9778 Tie2 Activation Combined with Vascular Endothelial Growth Factor Suppression.Ophthalmology, 2016. 123(8): p. 1722-1730.
  95. Bhat, M., et al., The kallikrein-kinin system in diabetic retinopathy.Prog Drug Res, 2014. 69: p. 111-43.
  96. http://www.modernretina.com/modern-retina/news/alg-1001-turning-machinery-angiogenesis.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Newsletter Signup

To keep up to date with our news and activities,
please leave your details below

GDPR Compliance Please indicate your consent for Retina International to contact you via the email address listed for the purposes of general alerts and newsletters.